Skip to main content

Chromogenic Multiplex Biomarker Profiling of Human FFPE Tissues Using UltraPlex Technology

Helen Snyder, PhD, Director of Preclinical Development and Strategic Partnerships Cell IDx

RELATED PRODUCTS
SHARE

Cell IDx’s UltraPlex chromogenic multiplex IHC technology allows the chromogenic detection of 3-4 markers simultaneously on a single tissue section using standard industry workflows. The protocol has been developed to run on the BOND RX autostainer using a single antigen retrieval step and is completed in ~4.5 hours. Adding to its broad utility, BOND RX the technology is primary antibody species independent. Images are obtained on all brightfield scanners in 5-15 minutes. This tissue conserving technology provides maximal information on small tissue samples. FFPE tissue-optimized panels for key biomarkers are available and other panels can be developed on request.

 

Learning Objectives

  • Learn how UltraPlex chromogenic multiplex  IHC  technology allows detection of multiple cell subtypes co-expressing multiple biomarkers using optimized chromogen combinations.
  • Learn how to expedite your data generation using a simple, fast, streamlined process combining UltraPlex chromogenic multiplex  IHC  panels with staining on the BOND RX staining platform and Aperio brightfield scanners.
  • Learn how to increase data generation from limited FFPE tissue samples including TMAs using this tissue conserving technology.

Leica Biosystems content is subject to the Leica Biosystems website terms of use, available at: Legal Notice. The content, including webinars, training presentations and related materials is intended to provide general information regarding particular subjects of interest to health care professionals and is not intended to be, and should not be construed as, medical, regulatory or legal advice. The views and opinions expressed in any third-party content reflect the personal views and opinions of the speaker(s)/author(s) and do not necessarily represent or reflect the views or opinions of Leica Biosystems, its employees or agents. Any links contained in the content which provides access to third party resources or content is provided for convenience only.

For the use of any product, the applicable product documentation, including information guides, inserts and operation manuals should be consulted.

Copyright © 2022 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.

About the presenter

Helen Snyder, PhD, Director of Preclinical Development and Strategic Partnerships Cell IDx

Received her PhD in immunology from the University of Cambridge, UK and trained as a postdoctoral fellow at Scripps Research Institute, La Jolla, California. Dr. Snyder has over 30 years' experience in immunology research, reagent development, preclinical development of biotherapeutics, and business development of immunoassay and immunodiagnostic products. She has held positions as Associate Professor at the University of California, San Diego, as well as Director of Immunology at Dynavax Technologies and key business development roles at both Solulink Biosciences and Cell IDx. Dr Snyder has over 40 papers and reviews in the areas of immune regulation and vaccine development and holds two patents.